Washington Examiner – by Katheryn Doyle
Drug industry lobbyists refused to attend a scheduled White House meeting with President Trump Tuesday to discuss his new rule limiting drug prices, forcing the White House to cancel the session.
Drug companies have criticized the move to tie certain drug costs to overseas pricing, which is known as the “most favored nations” rule. Some were surprised by the inclusion of the plan in Trump’s announcement, sources told Politico. Continue reading “Pharmaceutical officials refuse to meet with Trump following rule lowering drug prices”